Prelude Capital Management’s 4D Molecular Therapeutics FDMT Stock Holding History

Prelude Capital Management’s Portfolio FDMT Stock Details FDMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$101K	Sell	10,840 -4,930	-31%	-$42.9K	0.01%	1052
2025 Q4	$118K	Sell	15,770 -7,230	-31%	-$73.3K	0.01%	1159
2025 Q3	$200K	Buy	23,000 +2,300	+11%	+$13.7K	0.02%	955
2025 Q2	$76.8K	Sell	20,700 -1,800	-8%	-$6.33K	0.01%	936
2025 Q1	$72.7K	Buy	+22,500	New	+$106K	0.01%	1067
2023 Q1	–	Sell	-12,631	Closed	-$281K	–	1278
2022 Q4	$281K	Buy	+12,631	New	+$195K	0.01%	813

Other funds holding FDMT

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Prelude Capital Management's FDMT Position: Q1 2026 in Review

Prelude Capital Management reduced its 4D Molecular Therapeutics (FDMT) stake by 31% in Q1 2026, selling an estimated $42.9K and leaving 10,840 shares worth $101K. The position accounts for 0.01% of the portfolio, ranked #1052.

Prelude Capital Management first reported a position in FDMT in Q4 2022 and has held it in 6 quarters since. The position peaked at $281K in Q4 2022. 152 funds tracked by Wall St. Rank hold FDMT as of Q1 2026.

Prelude Capital Management held 10,840 shares of 4D Molecular Therapeutics worth $101K as of Q1 2026.
Prelude Capital Management sold 4,930 4D Molecular Therapeutics shares in Q1 2026, an estimated $42.9K.
4D Molecular Therapeutics made up 0.01% of Prelude Capital Management's portfolio in Q1 2026, its #1052 holding.
Prelude Capital Management first reported a position in 4D Molecular Therapeutics in Q4 2022 and has held it in 6 quarters since.
Prelude Capital Management's 4D Molecular Therapeutics position peaked at $281K in Q4 2022.
152 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q1 2026.

Based on Prelude Capital Management's 13F filing for Q1 2026, filed 15 May 2026.